NeuroOne discloses material weakness in controls, regains Nasdaq compliance after reverse split

Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

• high

  Management now concludes disclosure controls are ineffective due to insufficient segregation of duties in accounting functions, allowing individuals to initiate, process, and review transactions without independent oversight—a fundamental control deficiency not present in prior period.

  Controls & Procedures verify on EDGAR →
• high

  Management explicitly acknowledges substantial doubt about ability to continue as going concern, stating existing cash may not fund operations for twelve months—a material worsening from prior period when management believed cash would be sufficient.

  MD&A: Liquidity verify on EDGAR →
• high

  Company completed limited market release of OneRF TN Ablation System for trigeminal neuralgia in March 2026 and is evaluating distribution options, expanding addressable market beyond epilepsy into pain management.

  MD&A: Product Development verify on EDGAR →